Reading the tape
NASDAQ: XBIO
Xenetic Biosciences, Inc.
Healthcare · Biotechnology
Market Cap
$5.26M
52w High
$13.93
52w Low
$1.90
P/E
-2.64
Volume
75.39K
Outstanding Shares
1.70M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 6.92%Revenue (TTM): 19.04%FCF (TTM): 18.84%P/S: 22nd pct
What changed
The stock rose 6.92% over the last year. Revenue grew 19.04% over the trailing twelve months. Operating margin moved from -168.16% to -95.23%. Free cash flow grew 18.84% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -95.23%. A decisive move in revenue — currently up 19.04% — would be the clearest signal to resolve the ambiguity.
Company profile
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens.
CEOJames F. Parslow
SectorHealthcare
IndustryBiotechnology
Employees2
IPO dateJun 30, 2016
Valuation
Forward P/E—
EV/EBITDA1.48
Enterprise value-$4.19M
Stock splits
May 15, 2023↓ Reverse
Every 10 shares became 1
Jun 25, 2019↓ Reverse
Every 12 shares became 1
Jun 6, 2016↓ Reverse
Every 33 shares became 1
Profitability & growth
Revenue growth18.11%
Gross margin100%▲0.00%vs FY2024
Operating margin-95.23%▲43.37%vs FY2024
ROE-36.25%▲45.02%vs FY2024
Analyst consensus
RatingBuy
Target price—
1
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est — · Revenue est —
View